Politics and Government
Source : (remove) : STAT
RSS • JSON • XML • CSV
Politics and Government
Source : (remove) : STAT
RSS • JSON • XML • CSV

Metsera's drug shows potential in early clinical trial

  Copy link into your clipboard //politics-government.news-articles.net/content/ .. rug-shows-potential-in-early-clinical-trial.html
  Print publication without navigation Published in Politics and Government on by STAT
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
  And other biotech news stories brought to you by The Readout.

- Click to Lock Slider
The article from STAT News dated June 9, 2025, discusses several key developments in the biotech industry. Merck has acquired Eyebiotech for $3 billion to bolster its ophthalmology offerings, while Keros Therapeutics reported positive results from a Phase 2 trial of KER-050 for treating anemia in patients with myelodysplastic syndromes. Metsera, a new company focused on metabolic diseases, launched with $290 million in funding. Axsome Therapeutics received FDA approval for its migraine treatment, AXS-07. The European Medicines Agency (EMA) is set to review the safety of GLP-1 receptor agonists due to concerns over potential side effects. Additionally, the National Institutes of Health (NIH) is facing budget cuts that could impact research funding. Lastly, Amylin Pharmaceuticals is exploring a potential acquisition to expand its portfolio in diabetes and obesity treatments.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/06/09/biotech-news-merck-keros-metsera-axsome-ema-nih-cuts-amylin-the-readout/ ]